CytomX Therapeutics Inc. (NASDAQ:CTMX) does about 2.97M shares in volume on a normal day but saw 3308250 shares change hands in Monday trading. The company now has a market cap of 178.98M USD. Its current market price is $2.73, marking an increase of 8.33% compared to the previous close of $2.52. The 52 week high reached by this stock is $4.73 whilst the lowest price level in 52 weeks is $1.17. The script in recent trading has seen the stock touch a high of $2.80 and a low of $2.4915.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
CytomX Therapeutics Inc. (CTMX) has a 20-day trading average at $2.19 and the current price is -42.28% off the 52-week high compared with 133.33% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.82 and its 200-day simple moving average is $1.68. If we look at the stock’s price movements over the week, volatility stands at 8.18%, which increases to 9.38% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 69.16 to suggest the stock is neutral.
9 analysts observing the CytomX Therapeutics Inc. (CTMX) stock have set the 12-month price targets for the company’s shares at between $2.00 and $4.00. The consensus objective for the share price is $2.83, suggesting that the stock has a potential upside of 3.53% over the period. The median price target is 0.0% away from the current levels at $2.73.
FactSet Research has provided data showing that 9 brokerages have issued ratings for the stock. 1 analysts have rated it as a sell, while 1 advise that it is a overweight. 0 analysts have rated it as a buy and 7 have advised that investors hold their positions. The consensus recommendation rating is Hold and Wall Street’s advice is for investors to Hold the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 14, 2022 when BMO Capital Markets downgraded the stock to “Market Perform” and issued a price target of between $3 and $2.60. Wedbush also downgraded the stock to “Neutral” from Outperform on July 07, 2022 at a price target of $6-$2. Piper Sandler downgraded its price target at $10-$1.50.
The current price level is 28.32%, 52.55%, and 62.26% away from its SMA20, SMA50, and SMA200 respectively, with the CTMX price moving below the 50-day SMA on January 23. CytomX Therapeutics Inc. (CTMX) stock is down -4.55% over the week and 82.00% over the past month. Its price is 70.62% year-to-date and -34.38% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2022, with the company’s earnings per share (EPS) of -$0.37 below consensus estimates by -$0.01. The company’s next earnings report is expected on 05/04/2023, with forecasts estimating quarterly EPS at -$0.31 and -$1.3 for whole year. Expected sales for next quarter are $18.89 million, which analysts say will come at $70.3 million for the current fiscal year and next year at $64.49 million. In addition, estimates put the company’s current quarterly revenue at an average of $17.94 million.
Its 12-month price target is $2.73. To reach the target analysts have set, the stock logically needs to grow 3.53 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $2.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $4.00.
Outstanding shares total 65.91M with insiders holding 1.31% of the shares and institutional holders owning 78.99% of the company’s common stock. The company has a return on investment of -93.70% and return on equity of -166.30%. The beta has a value of 0.45. Price to book ratio is 6.35 and price to sales ratio is 2.49.
Candriam Equities L – Oncology Im isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which added 46414.0 shares to end up with 1,468,702 shares worth $2.35 million.
